Literature DB >> 28850821

Ultrasonographic evaluation of intra-abdominal fat distribution and study of its influence on subclinical atherosclerosis in women with polycystic ovarian syndrome.

Priyadarshini Tripathy1, Asutosh Sahu2, Mahija Sahu3, Attila Nagy4.   

Abstract

OBJECTIVES: To evaluate abdominal fat distribution and cardiovascular disease (CVD) risk factors in women with polycystic ovarian syndrome (PCOS) and to determine the independent risk factors for subclinical atherosclerosis. STUDY
DESIGN: One hundred and twenty-four women with PCOS were compared with 118 age and BMI-matched controls. Abdominal obesity was assessed as the waist-to-hip ratio (WHR) and abdominal fat distribution was measured as subcutaneous fat thickness (SFT), pre-peritoneal fat thickness (PFT) and visceral fat thickness (VFT) using Ultrasound (US). Markers of subclinical atherosclerosis (carotid intima-media thickness (CIMT) and brachial artery flow-mediated dilation (FMD)) and other CVD risk factors such as fasting glucose, fasting insulin (FIN), insulin resistance (HOMA-IR), androgens and lipid levels were measured.
RESULTS: In comparison to controls, PCOS women had increased VFT and subclinical atherosclerosis. PCOS women also had higher FIN and lower levels of high-density lipoprotein cholesterol (HDL-C) and an elevated total cholesterol (TC) to HDL-C ratio. In PCOS women, VFT showed a strong association with CIMT and WHR showed a strong association with FIN and HOMA-IR; however these associations were weak in controls. Multiple regression analysis revealed VFT as the strongest independent predictor of CIMT in PCOS women whereas age was the only independent predictor of CIMT and FMD in controls.
CONCLUSIONS: While age can be an independent baseline risk factor for subclinical atherosclerosis in normal menstruating women, excess visceral fat accumulation is the most important predictor of atherosclerosis in PCOS patients.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Carotid intima media thickness; Fat distribution; Flow mediated dilation; Polycystic ovarian syndrome; Visceral fat

Mesh:

Year:  2017        PMID: 28850821     DOI: 10.1016/j.ejogrb.2017.08.011

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  12 in total

1.  Metabolic syndrome and the risk of cardiovascular complications in young patients with different phenotypes of polycystic ovary syndrome.

Authors:  Anna Krentowska; Agnieszka Łebkowska; Małgorzata Jacewicz-Święcka; Justyna Hryniewicka; Monika Leśniewska; Agnieszka Adamska; Irina Kowalska
Journal:  Endocrine       Date:  2021-01-13       Impact factor: 3.633

2.  [Research progress on the role of pentraxin 3 in polycystic ovary syndrome].

Authors:  Wei Wu; Jian Xu
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-10-25

3.  ApoB48-Lipoproteins Are Associated with Cardiometabolic Risk in Adolescents with and without Polycystic Ovary Syndrome.

Authors:  Donna F Vine; Lawrence J Beilin; Sally Burrows; Rae-Chi Huang; Martha Hickey; Roger Hart; Spencer D Proctor; Trevor A Mori
Journal:  J Endocr Soc       Date:  2020-05-26

Review 4.  Optimizing HIV prevention and care for transgender adults.

Authors:  Jordan E Lake; Jesse L Clark
Journal:  AIDS       Date:  2019-03-01       Impact factor: 4.177

5.  [Efficacy and metabolic safety of long-term treatment with ethinyl oestradiol/cyproterone and desogestrel/ethinyl oestradiol tablets in women with polycystic ovary syndrome].

Authors:  Jun Zhang; Mi Su; Liangzhi Xu; Zhilan Yang; Weiyao Yin; Ying Nie; Xiaoyong Qiao; Ran Cheng; Yaxian Ma
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-07-30

Review 6.  Assessment of Early Markers of Cardiovascular Risk in Polycystic Ovary Syndrome.

Authors:  Krystallenia I Alexandraki; Eleni A Kandaraki; Kalliopi-Anna Poulia; Christina Piperi; Eirini Papadimitriou; Theodoros G Papaioannou
Journal:  touchREV Endocrinol       Date:  2021-04-28

Review 7.  Cardiometabolic risk in polycystic ovary syndrome.

Authors:  Katica Bajuk Studen; Marija Pfeifer
Journal:  Endocr Connect       Date:  2018-05-29       Impact factor: 3.335

8.  The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome.

Authors:  Zeeshan Javed; Maria Papageorgiou; Leigh A Madden; Alan S Rigby; Eric S Kilpatrick; Stephen L Atkin; Thozhukat Sathyapalan
Journal:  Endocr Connect       Date:  2020-06       Impact factor: 3.335

Review 9.  Novel insight into perirenal adipose tissue: A neglected adipose depot linking cardiovascular and chronic kidney disease.

Authors:  Na Huang; En-Wen Mao; Ning-Ning Hou; Yong-Ping Liu; Fang Han; Xiao-Dong Sun
Journal:  World J Diabetes       Date:  2020-04-15

10.  Lower sexual satisfaction in women with polycystic ovary syndrome and metabolic syndrome.

Authors:  Małgorzata Kałużna; Agnieszka Nomejko; Aleksandra Słowińska; Katarzyna Wachowiak-Ochmańska; Katarzyna Pikosz; Katarzyna Ziemnicka; Marek Ruchała
Journal:  Endocr Connect       Date:  2021-08-30       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.